跳至主要内容
临床试验/EUCTR2014-002226-13-DK
EUCTR2014-002226-13-DK进行中(未招募)1 期

A multimodality imaging approach for early detection and prediction of cardiotoxicity in Doxorubicin-treated patients with malignant lymphom - Advanced imaging for identifying doxorubicin-induced cardiotoxicity in lymphoma patients

Rigshospitalet0 个研究点目标入组 100 人开始时间: 2014年11月26日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • -Newly diagnosed Hodgkin or non-Hodgkin lymphoma
  • -Intended curative chemotherapeutic treatment including doxorubicin
  • -Age > 18 years
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 70
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 30

排除标准

  • -Planned mediastinal radiation therapy involving the heart (patients receiving only upper mediastinal radiation therapy can still participate)
  • -Previous chemotherapeutic treatment
  • -Previous mediastinal radiation therapy
  • -Pre-existing HF of any cause (LVEF < 50%)
  • -Significant renal disease (eGFR measured within 3 weeks prior to start of chemotherapy should be > 30ml/min/1.73 m2)
  • -Impaired liver function (bilirubin > 20 µmol/l)
  • -Contraindications for MR scan (severe claustrophobia, implanted metallic foreign bodies etc.)
  • -Contraindications for PET scan (adenosine intolerance, 2nd or 3rd degree AV block, long QT syndrome, unstable angina pectoris, sinus node dysfunction)
  • -Unwillingness to participate
  • -Unable to give informed consent or unlikely to comply with follow-up

研究者

相似试验

Advanced imaging for identifying... | 临床试验